• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by CASI Pharmaceuticals Inc.

    1/20/26 9:33:06 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CASI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)


    CASI Pharmaceuticals, Inc.

    (Name of Issuer)


    Ordinary Shares, par value US$0.0001 per share

    (Title of Class of Securities)


    G1933S101

    (CUSIP Number)


    Chi Sing Ho
    IDG Capital Management (HK) Company Ltd, 99 Queen's Road, Central
    Hong Kong, K3, 00000
    852-3903 1333

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    09/30/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    G1933S101


    1 Name of reporting person

    IDG-Accel China Growth Fund III L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    855,222.00
    8Shared Voting Power

    60,628.00
    9Sole Dispositive Power

    855,222.00
    10Shared Dispositive Power

    60,628.00
    11Aggregate amount beneficially owned by each reporting person

    915,850.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.5 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The value in lines 7 and 9 represents 855,222 ordinary shares of the Issuer held by the Reporting Person. The value in lines 8 and 10 represents 60,628 ordinary shares of the Issuer held by IDG-Accel China III Investors L.P. ("IDG-Accel Investors"). Percent of Class Represented by Amount in Row (11) is based on 20,548,273 ordinary shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025.


    SCHEDULE 13D

    CUSIP No.
    G1933S101


    1 Name of reporting person

    IDG-Accel China III Investors L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    60,628.00
    8Shared Voting Power

    855,222.00
    9Sole Dispositive Power

    60,628.00
    10Shared Dispositive Power

    855,222.00
    11Aggregate amount beneficially owned by each reporting person

    915,850.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.5 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The value in lines 7 and 9 represents 60,628 ordinary shares of the Issuer held by the Reporting Person. The value in lines 8 and 10 represents 855,222 ordinary shares of the Issuer held by IDG-Accel China Growth Fund III L.P. ("IDG-Accel Growth"). Percent of Class Represented by Amount in Row (11) is based on 20,548,273 ordinary shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025.


    SCHEDULE 13D

    CUSIP No.
    G1933S101


    1 Name of reporting person

    IDG-Accel China Growth Fund III Associates L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    855,222.00
    8Shared Voting Power

    60,628.00
    9Sole Dispositive Power

    855,222.00
    10Shared Dispositive Power

    60,628.00
    11Aggregate amount beneficially owned by each reporting person

    915,850.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.5 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The value in lines 7 and 9 represents 855,222 ordinary shares of the Issuer held by IDG-Accel Growth. The Reporting Person is the sole general partner of IDG-Accel Growth. By virtue of this affiliation, the Reporting Person may be deemed to have sole voting and dispositive power with respect to all these securities. The value in lines 8 and 10 represents 60,628 ordinary shares of the Issuer held by IDG-Accel Investors. The Reporting Person has the same general partner, IDG-Accel China Growth Fund GP III Associates Ltd. as IDG-Accel Investors. By virtue of this affiliation, the Reporting Person may be deemed to be under common control with IDG-Accel Investors and thus share voting and dispositive power with respect to these shares. Percent of Class Represented by Amount in Row (11) is based on 20,548,273 ordinary shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025.


    SCHEDULE 13D

    CUSIP No.
    G1933S101


    1 Name of reporting person

    IDG-Accel China Growth Fund GP III Associates Ltd.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    915,850.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    915,850.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    915,850.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.5 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    The value in lines 7 and 9 represents (i) 855,222 ordinary shares of the Issuer held by IDG-Accel Growth; and (ii) 60,628 ordinary shares of the Issuer held by IDG-Accel Investors. The Reporting Person is the ultimate general partner of both IDG-Accel Growth and IDG-Accel Investors. By virtue of this affiliation, the Reporting Person may be deemed to have voting and dispositive power with respect to all these shares. Percent of Class Represented by Amount in Row (11) is based on 20,548,273 ordinary shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025.


    SCHEDULE 13D

    CUSIP No.
    G1933S101


    1 Name of reporting person

    Ho Chi Sing
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    915,850.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    915,850.00
    11Aggregate amount beneficially owned by each reporting person

    915,850.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.5 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    The value in lines 8 and 10 represents (i) 855,222 ordinary shares of the Issuer held by IDG-Accel Growth; and (ii) 60,628 ordinary shares of the Issuer held by IDG-Accel Investors. The Reporting Person and Quan Zhou are directors and shareholders of IDG-Accel China Growth Fund GP III Associates Ltd., the ultimate general partner of IDG-Accel Growth and IDG-Accel Investors, thus may be deemed to share voting and dispositive power with respect to all these shares. Percent of Class Represented by Amount in Row (11) is based on 20,548,273 ordinary shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025.


    SCHEDULE 13D

    CUSIP No.
    G1933S101


    1 Name of reporting person

    Zhou Quan
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    76,788.00
    8Shared Voting Power

    915,850.00
    9Sole Dispositive Power

    76,788.00
    10Shared Dispositive Power

    915,850.00
    11Aggregate amount beneficially owned by each reporting person

    992,638.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.8 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    The value in lines 7 and 9 represents 76,788 ordinary shares of the Issuer issuable upon exercise of certain options issued by the Issuer to Quan Zhou. The value in lines 8 and 10 represents (i) 855,222 ordinary shares of the Issuer held by IDG-Accel Growth; and (ii) 60,628 ordinary shares of the Issuer held by IDG-Accel Investors. The Reporting Person and Chi Sing Ho are directors and shareholders of IDG-Accel China Growth Fund GP III Associates Ltd., the ultimate general partner of IDG-Accel Growth and IDG-Accel Investors, thus may be deemed to share voting and dispositive power with respect to all these shares. Percent of Class Represented by Amount in Row (11) is based on 20,548,273 ordinary shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Ordinary Shares, par value US$0.0001 per share
    (b)Name of Issuer:

    CASI Pharmaceuticals, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    1701-1702, CHINA CENTRAL OFFICE TOWER 1, NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT, BEIJING, CHINA , 100025.
    Item 1 Comment:
    This Amendment No. 7 amends the Statement on Schedule 13D dated January 30, 2012 as amended by Amendment No. 1 dated February 2, 2012, Amendment No. 2 dated June 11, 2012, Amendment No. 3 dated March 6, 2013, Amendment No. 4 dated March 20, 2018, Amendment No. 5 dated February 21, 2023 and Amendment No. 6 dated February 3, 2025 (as so amended, the "Original Schedule 13D") and is being filed to reflect changes in the percentage of Ordinary Shares beneficially owned by the Reporting Persons due to increase in the amount of total issued and outstanding Ordinary Shares of the Issuer over time. Except as amended and supplemented herein, the information set forth in the Original Schedule 13D remains unchanged. Capitalized terms used herein have meanings as assigned thereto in the Original Schedule 13D, unless defined herein.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5(a) of the Original Schedule 13D is hereby amended and restated in its entirety as follows: The aggregate number and percentage of the Ordinary Shares beneficially owned by each Reporting Person is set forth on the cover pages to this Statement on Schedule 13D and is incorporated by reference herein. The ownership percentage appearing on such pages has been calculated based on a total of 20,548,273 Ordinary Shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025. The Reporting Persons disclaim membership in any "group" with any person other than the Reporting Persons. The filing of this Statement on Schedule 13D by the Reporting Persons shall not be considered an admission that such Reporting Persons, for the purpose of Section 13(d) of the Exchange Act, are the beneficial owners of any of the Ordinary Shares covered in this Statement on Schedule 13D, and the Reporting Persons expressly disclaim such beneficial ownership.
    (b)
    Item 5(b) of the Original Schedule 13D is hereby amended and restated in its entirety as follows: For each Reporting Person, the number of the Ordinary Shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on the cover pages to this Statement on Schedule 13D, and are incorporated herein by reference.
    (c)
    Item 5(c) of the Original Schedule 13D is hereby amended and restated in its entirety as follows: None of the Reporting Persons has engaged in any transactions in the Issuer's securities during the past sixty days other than as disclosed herein.
    (e)
    Item 5(e) of the Original Schedule 13D is hereby amended and restated in its entirety as follows: Each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the Ordinary Shares of the Issuer on September 30, 2025.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    IDG-Accel China Growth Fund III L.P.
     
    Signature:/s/ Chi Sing Ho on behalf of IDG-Accel China Growth Fund GP III Associates Ltd., ultimate General Partner of IDG-Accel China Growth Fund III L.P.
    Name/Title:Chi Sing Ho / Authorized Signatory
    Date:01/20/2026
     
    IDG-Accel China III Investors L.P.
     
    Signature:/s/ Chi Sing Ho on behalf of IDG-Accel China Growth Fund GP III Associates Ltd., General Partner of IDG-Accel China III Investors L.P.
    Name/Title:Chi Sing Ho / Authorized Signatory
    Date:01/20/2026
     
    IDG-Accel China Growth Fund III Associates L.P.
     
    Signature:/s/ Chi Sing Ho on behalf of IDG-Accel China Growth Fund GP III Associates Ltd., General Partner of IDG-Accel China Growth Fund III Associates L.P.
    Name/Title:Chi Sing Ho / Authorized Signatory
    Date:01/20/2026
     
    IDG-Accel China Growth Fund GP III Associates Ltd.
     
    Signature:/s/ Chi Sing Ho
    Name/Title:Chi Sing Ho / Authorized Signatory
    Date:01/20/2026
     
    Ho Chi Sing
     
    Signature:/s/ Ho Chi Sing
    Name/Title:Ho Chi Sing
    Date:01/20/2026
     
    Zhou Quan
     
    Signature:/s/ Quan Zhou
    Name/Title:Quan Zhou
    Date:01/20/2026
    Get the next $CASI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CASI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CASI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

    BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the first patient has been dosed in the Phase 1/2 trial to evaluate the safety and tolerability of CID-103 in adult patients with chronic Immune Thrombocytopenia (ITP) in China."Dosing the first patient in our phase 1/2 study marks a significant milestone for both CID-103 program and chronic ITP patients who have limited treatment options," said Dr. Wei-Wu He, Chairman and CEO of CASI, "The rapid execution underscores our commitment to accelerating clinic

    1/6/25 8:00:00 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

    BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024.Dr. Wei-Wu He, Chairman and CEO of CASI, said "The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases. We just announced the Center for Drug Evaluation (CDE) of China's Nationa

    11/15/24 8:00:00 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

    BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) to proceed with a phase 1/2 study of CID-103 in adults patients with chronic Immune Thrombocytopenia (ITP) in China. This China study is part of the global study that was approved by the US FDA in May 2024.CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that ha

    10/24/24 8:00:00 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CASI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by CASI Pharmaceuticals Inc.

    SCHEDULE 13D/A - CASI Pharmaceuticals, Inc. (0001962738) (Subject)

    1/29/26 7:21:16 PM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by CASI Pharmaceuticals Inc.

    D - CASI Pharmaceuticals, Inc. (0001962738) (Filer)

    1/28/26 7:17:15 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by CASI Pharmaceuticals Inc.

    D - CASI Pharmaceuticals, Inc. (0001962738) (Filer)

    1/28/26 7:13:08 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Zukiwski Alexander A

    4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)

    9/9/22 4:01:37 PM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Huang James bought $229,662 worth of shares (55,573 units at $4.13)

    4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)

    9/8/22 6:51:39 PM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Huang James bought $139,036 worth of shares (37,196 units at $3.74)

    4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)

    9/2/22 7:35:18 PM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on CASI Pharma with a new price target

    BTIG Research initiated coverage of CASI Pharma with a rating of Buy and set a new price target of $4.00

    5/18/21 6:41:48 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on CASI Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of CASI Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $3.50 previously

    5/14/21 6:40:01 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on CASI Pharmaceuticals with a new price target

    Mizuho initiated coverage of CASI Pharmaceuticals with a rating of Buy and set a new price target of $3.80

    4/26/21 7:19:24 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CASI
    Leadership Updates

    Live Leadership Updates

    View All

    CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

    BEIJING, July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capi

    7/8/24 7:30:00 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CASI
    Financials

    Live finance-specific insights

    View All

    Ligand Reports Second Quarter 2024 Financial Results

    Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

    8/6/24 4:01:00 PM ET
    $AGEN
    $AMGN
    $CASI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ligand Reports First Quarter 2024 Financial Results

    Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio. Simultaneously, we continue to build our portfolio of development stage royalty assets to deliver future growth," said Todd Davis, CEO of Ligand. "We continue to originate a robust pipe

    5/7/24 4:00:00 PM ET
    $AMGN
    $CASI
    $JAZZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

    BEIJING, July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the United States ("US") CB-5339 Investigational New Drug ("IND") application.

    7/20/23 8:00:00 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CASI Pharmaceuticals Inc.

    SC 13G/A - CASI Pharmaceuticals, Inc. (0001962738) (Subject)

    10/29/24 4:05:28 PM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by CASI Pharmaceuticals Inc.

    SC 13D/A - CASI Pharmaceuticals, Inc. (0001962738) (Subject)

    8/12/24 8:27:51 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by CASI Pharmaceuticals Inc.

    SC 13G - CASI Pharmaceuticals, Inc. (0001962738) (Subject)

    7/25/24 8:48:03 PM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care